<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36858287</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2666-9919</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Infectious diseases now</Title><ISOAbbreviation>Infect Dis Now</ISOAbbreviation></Journal><ArticleTitle>COVID-19 long-term sequelae: Omicron versus Alpha and Delta variants.</ArticleTitle><Pagination><StartPage>104688</StartPage><MedlinePgn>104688</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.idnow.2023.104688</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2666-9919(23)00050-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The study aimed to assess the association between three predominant SARS-CoV-2 variants (Alpha, Delta, and Omicron) and the risk of developing long COVID (persistence of physical, medical, and cognitive symptoms more than 4&#xa0;weeks after infection), post-COVID-19 syndrome (symptoms extending beyond 12&#xa0;weeks), and viral persistence (testing positive beyond 4&#xa0;weeks despite clinical resolution).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Retrospective study of 325 patients hospitalized for COVID-19 with genomic sequencing information. For each SARS-CoV-2 variant, sample characteristics, frequency of symptoms, and long-term sequelae were compared using Chi-squared test, Fisher's exact test, Kruskal-Wallis test, and Dunn's test as appropriate. Odds ratios (OR) were calculated using logistic regression models to assess the association of risk factors and sequelae.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The adjusted model showed that the Omicron (vs Alpha) variant (OR, 0.30; 95% CI 0.16-0.56), admission to ICU (OR, 1.14; 95% CI 1.05-1.23), and being treated with antiviral or immunomodulatory drugs (OR, 2.01; 95% CI 1.23-3.27) predicted long COVID and post-COVID-19 syndrome. Viral persistence showed no difference between variants.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The Omicron variant was associated with significantly lower odds of developing long-term sequelae from COVID-19 compared with previous variants, while severity of illness indicators increased the risk. Vaccination status, age, sex, and comorbidities were not found to predict sequelae development. This information has implications for both health managers and clinicians when deciding on the appropriate clinical management and subsequent outpatient follow-up of these patients. More studies with non-hospitalized patients are still necessary.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier Masson SAS.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hern&#xe1;ndez-Aceituno</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Direcci&#xf3;n General de Salud P&#xfa;blica, Canary Islands, Spain; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain. Electronic address: Anahdez989@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Hern&#xe1;ndez</LastName><ForeName>Abigail</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Direcci&#xf3;n General de Salud P&#xfa;blica, Canary Islands, Spain; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larumbe-Zabala</LastName><ForeName>Eneko</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Direcci&#xf3;n General de Salud P&#xfa;blica, Canary Islands, Spain; Fundaci&#xf3;n Canaria Instituto de Investigaci&#xf3;n Sanitaria de Canarias (FIISC), Canary Islands, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Infect Dis Now</MedlineTA><NlmUniqueID>101775152</NlmUniqueID><ISSNLinking>2666-9919</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Post-COVID-19</Keyword><Keyword MajorTopicYN="N">Sequelae</Keyword><Keyword MajorTopicYN="N">Variants</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>1</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36858287</ArticleId><ArticleId IdType="pmc">PMC9970656</ArticleId><ArticleId IdType="doi">10.1016/j.idnow.2023.104688</ArticleId><ArticleId IdType="pii">S2666-9919(23)00050-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tsai P.H., Lai W.Y., Lin Y.Y., Luo Y.H., Lin Y.T., Chen H.K., et al. Clinical manifestation and disease progression in COVID-19 infection. J Chinese Med Assoc. 2021;31(841):3&#x2013;8. doi: 10.1097/JCMA.0000000000000463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JCMA.0000000000000463</ArticleId><ArticleId IdType="pubmed">33230062</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: managing the long-term effects of COVID-19 2020 December:1&#x2013;106. https://www.nice.org.uk/guidance/NG188 (accessed October 12, 2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., et al. Post-acute COVID-19 syndrome. Nat Med. 2021;22(274):601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;224:e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennings G., Monaghan A., Xue F., Mockler D., Romero-Ortu&#xf1;o R. A Systematic review of persistent symptoms and residual abnormal functioning following Acute COVID-19: ongoing symptomatic phase vs. Post-COVID-19 syndrome. J Clin Med. 2021;16(1024):5913. doi: 10.3390/jcm10245913.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10245913</ArticleId><ArticleId IdType="pmc">PMC8708187</ArticleId><ArticleId IdType="pubmed">34945213</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H., Raza S., Nowell J., Young M., Edison P. Long covid&#x2014;mechanisms, risk factors, and management. BMJ. 2021;26:n1648. doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynberg E., Han A.X., Boyd A., van Willigen H.D.G., Verveen A., Lebbink R., et al. The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort study. Vaccine. 2022;4032:4424&#x2013;4431. doi: 10.1016/j.vaccine.2022.05.090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.05.090</ArticleId><ArticleId IdType="pmc">PMC9170535</ArticleId><ArticleId IdType="pubmed">35725782</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institutes of Health (NIH). COVID-19 Treatment Guidelines.Therapeutic Management of Hospitalized Adults With COVID-19 2022:68&#x2013;79. https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/hospitalized-adults--therapeutic-management/ (accessed October 12, 2022).</Citation></Reference><Reference><Citation>Fintzi J., Bonnett T., Sweeney D.A., Huprikar N.A., Ganesan A., Frank M.G., et al. Deconstructing the treatment effect of remdesivir in the adaptive coronavirus disease 2019 (COVID-19) treatment trial-1: implications for critical care resource utilization. Clin Infect Dis. 2022;74(12):2209&#x2013;2217. doi: 10.1093/cid/ciab712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab712</ArticleId><ArticleId IdType="pmc">PMC8499739</ArticleId><ArticleId IdType="pubmed">34409989</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima Y., Nakakubo S., Kamada K., Yamashita Y., Takei N., Nakamura J., et al. Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective study. J Med Virol. 2022;94(12):5702&#x2013;5712. doi: 10.1002/jmv.28037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28037</ArticleId><ArticleId IdType="pmc">PMC9538820</ArticleId><ArticleId IdType="pubmed">35916111</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministerio de Sanidad (Spain). Integraci&#xf3;n de la secuenciaci&#xf3;n gen&#xf3;mica en la vigilancia del SARS-CoV-2 2022:1&#x2013;8. https://www.sanidad.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Integracion_de_la_secuenciacion_genomica-en_la_vigilancia_del_SARS-CoV-2.pdf (accessed October 12, 2022).</Citation></Reference><Reference><Citation>Cole T.J., Lobstein T. Extended international (IOTF) body mass index cut-offs for thinness, overweight and obesity. Pediatr Obes. 2012;74:284&#x2013;294. doi: 10.1111/j.2047-6310.2012.00064.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2047-6310.2012.00064.x</ArticleId><ArticleId IdType="pubmed">22715120</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosetti C., Rognoni M., Ciampichini R., Paroni L., Scala M., Cavalieri d&#x2019;Oro L., et al. A real world analysis of COVID-19 impact on hospitalizations in older adults with chronic conditions from an Italian region. Sci Rep. 2022;12(121):13704. doi: 10.1038/s41598-022-17941-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-17941-2</ArticleId><ArticleId IdType="pmc">PMC9374749</ArticleId><ArticleId IdType="pubmed">35962037</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung M., Babik J.M. COVID-19 in immunocompromised hosts: what we know so far. Clin Infect Dis. 2021;27(722):340&#x2013;350. doi: 10.1093/cid/ciaa863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa863</ArticleId><ArticleId IdType="pmc">PMC7337668</ArticleId><ArticleId IdType="pubmed">33501974</ArticleId></ArticleIdList></Reference><Reference><Citation>Gajurel K. Persistently positive severe acute respiratory syndrome coronavirus 2 (SARS-COV2) nasopharyngeal PCR in a kidney transplant recipient. Transpl Infect Dis. 2020;27:226. doi: 10.1111/tid.13408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tid.13408</ArticleId><ArticleId IdType="pmc">PMC7404596</ArticleId><ArticleId IdType="pubmed">32652872</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrenn J.O., Pakala S.B., Vestal G., Shilts M.H., Brown H.M., Bowen S.M., et al. COVID-19 severity from Omicron and Delta SARS-CoV-2 variants. Influenza Other Respi Viruses. 2022;13(165):832&#x2013;836. doi: 10.1111/irv.12982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12982</ArticleId><ArticleId IdType="pmc">PMC9111734</ArticleId><ArticleId IdType="pubmed">35415869</ArticleId></ArticleIdList></Reference><Reference><Citation>Jassat W., Abdool Karim S.S., Mudara C., Welch R., Lovelyn Ozougwu L., Groome M.J., et al. Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study. Lancet Glob Heal. 2022;107:e961&#x2013;e969. doi: 10.1016/S2214-109X(22)00114-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(22)00114-0</ArticleId><ArticleId IdType="pmc">PMC9116895</ArticleId><ArticleId IdType="pubmed">35597249</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M., Pujol J.C., Spector T.D., Ourselin S., Steves C.J. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399(10343):2263&#x2013;2264. doi: 10.1016/S0140-6736(22)00941-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C., Cancela-Cilleruelo I., Rodr&#xed;guez-Jim&#xe9;nez J., G&#xf3;mez-Mayordomo V., Pellicer-Valero O.J., Mart&#xed;n-Guerrero J.D., et al. Associated-onset symptoms and Post-COVID-19 symptoms in hospitalized COVID-19 survivors infected with wuhan, alpha or delta SARS-CoV-2 variant. Pathogens. 2022;25(117):725. doi: 10.3390/pathogens11070725.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11070725</ArticleId><ArticleId IdType="pmc">PMC9320021</ArticleId><ArticleId IdType="pubmed">35889971</ArticleId></ArticleIdList></Reference><Reference><Citation>Canas LS, Molteni E, Deng J, Sudre CH, Murray B, Kerfoot E, et al. Profiling post-COVID syndrome across different variants of SARS-CoV-2. MedRxiv. 2022 January 1:2022.07.28.22278159. 10.1101/2022.07.28.22278159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.07.28.22278159</ArticleId></ArticleIdList></Reference><Reference><Citation>Imzil A, Essaid Y, Moubachir H, Serhane H. Post covid-19 manifestations in the omicron wave. 10.01 - Respir. Infect. bronchiectasis, European Respiratory Society; 2022 September 4, p. 1519.</Citation></Reference><Reference><Citation>Shen X., Wang P., Shen J., Jiang Y., Wu L., Nie X., et al. Neurological Manifestations of hospitalized patients with mild to moderate infection with SARS-CoV-2 Omicron variant in Shanghai. China J Infect Public Health. 2023;162:155&#x2013;162. doi: 10.1016/j.jiph.2022.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2022.12.005</ArticleId><ArticleId IdType="pmc">PMC9726211</ArticleId><ArticleId IdType="pubmed">36535135</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunada N., Nakano Y., Otsuka Y., Tokumasu K., Honda H., Sakurada Y., et al. Characteristics of Sleep Disturbance in Patients with Long COVID: A Retrospective Observational Study in Japan. J Clin Med. 2022;9(1124):7332. doi: 10.3390/jcm11247332.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11247332</ArticleId><ArticleId IdType="pmc">PMC9783729</ArticleId><ArticleId IdType="pubmed">36555948</ArticleId></ArticleIdList></Reference><Reference><Citation>Mumtaz A., Sheikh A.A.E., Khan A.M., Khalid S.N., Khan J., Nasrullah A., et al. COVID-19 Vaccine and Long COVID: A Scoping Review. Life (Basel) 2022;12(7):1066. doi: 10.3390/life12071066.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life12071066</ArticleId><ArticleId IdType="pmc">PMC9324565</ArticleId><ArticleId IdType="pubmed">35888154</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte K.I., Catahay J.A., Velasco J.V., Adriel Pastrana A., Ver A.T., Pangilinan F.C., et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. EClinicalMedicine. 2022;53:101624. doi: 10.1016/j.eclinm.2022.101624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101624</ArticleId><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Yang H., Hou C., Chen W., Zhang H., Ying Z., et al. COVID-19 related outcomes among individuals with neurodegenerative diseases: a cohort analysis in the UK biobank. BMC Neurol. 2022;7(221):15. doi: 10.1186/s12883-021-02536-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-021-02536-7</ArticleId><ArticleId IdType="pmc">PMC8739517</ArticleId><ArticleId IdType="pubmed">34996388</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin S., O&#x2019;Connor R., Sivan M. Long COVID and chronic COVID syndromes. J Med Virol. 2021;30(933):1242&#x2013;1243. doi: 10.1002/jmv.26587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26587</ArticleId><ArticleId IdType="pmc">PMC7675759</ArticleId><ArticleId IdType="pubmed">33034893</ArticleId></ArticleIdList></Reference><Reference><Citation>Righi E., Mirandola M., Mazzaferri F., Dossi G., Razzaboni E., Zaffagnini A., et al. Determinants of persistence of symptoms and impact on physical and mental wellbeing in Long COVID: A prospective cohort study. J Infect. 2022;844:566&#x2013;572. doi: 10.1016/j.jinf.2022.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2022.02.003</ArticleId><ArticleId IdType="pmc">PMC8828388</ArticleId><ArticleId IdType="pubmed">35150765</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Boglione L., Meli G., Poletti F., Rostagno R., Moglia R., Cantone M., et al. Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect? QJM An Int J Med. 2022;114(12):865&#x2013;871. doi: 10.1093/qjmed/hcab297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcab297</ArticleId><ArticleId IdType="pmc">PMC8690187</ArticleId><ArticleId IdType="pubmed">34850210</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouffak S., Shubbar Q., Saleh E., El-Awady R. Recent advances in management of COVID-19: A review. Biomed Pharmacother. 2021;143:112107. doi: 10.1016/j.biopha.2021.112107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2021.112107</ArticleId><ArticleId IdType="pmc">PMC8390390</ArticleId><ArticleId IdType="pubmed">34488083</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizk J.G., Kalantar-Zadeh K., Mehra M.R., Lavie C.J., Rizk Y., Forthal D.N. Pharmaco-Immunomodulatory Therapy in COVID-19. Drugs. 2020;21(8013):1267&#x2013;1292. doi: 10.1007/s40265-020-01367-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-020-01367-z</ArticleId><ArticleId IdType="pmc">PMC7372203</ArticleId><ArticleId IdType="pubmed">32696108</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). StatPearls I[Nternet]. 2022. https://www.ncbi.nlm.nih.gov/books/NBK554776/ (accessed October 12, 2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">32150360</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A.D., VanElzakker M.B. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021;23:12. doi: 10.3389/fmicb.2021.698169.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang D., Zhao P., Zhang D., Dong J.H., Xu Z., Yang G., et al. Persistent viral presence determines the clinical course of the disease in COVID-19. J Allergy Clin Immunol Pract. 2020;8(8):2585&#x2013;2591.e1. doi: 10.1016/j.jaip.2020.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaip.2020.06.015</ArticleId><ArticleId IdType="pmc">PMC7305869</ArticleId><ArticleId IdType="pubmed">32574840</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodin P., Casari G., Townsend L., O'Farrelly C., Tancevski I., L&#xf6;ffler-Ragg J., et al. Studying severe long COVID to understand post-infectious disorders beyond COVID-19. Nat Med. 2022;28(5):879&#x2013;882. doi: 10.1038/s41591-022-01766-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01766-7</ArticleId><ArticleId IdType="pubmed">35383311</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler D.M. The costs of long COVID. JAMA Heal Forum. 2022;12(35):e221809.</Citation><ArticleIdList><ArticleId IdType="pubmed">36219031</ArticleId></ArticleIdList></Reference><Reference><Citation>Erinoso O. Post-COVID-19 condition: current evidence and unanswered questions. Lancet Glob Heal. 2022;109:e1210&#x2013;e1211. doi: 10.1016/S2214-109X(22)00323-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(22)00323-0</ArticleId><ArticleId IdType="pmc">PMC9363039</ArticleId><ArticleId IdType="pubmed">35961329</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong S.J. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Auckl) 2021;3(5310):737&#x2013;754. doi: 10.1080/23744235.2021.1924397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2021.1924397</ArticleId><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Patcai J. Is &#x2018;Long Covid&#x2019; similar to &#x2018;Long SARS&#x2019;? Oxford Open Immunol. 2022;11:31. doi: 10.1093/oxfimm/iqac002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfimm/iqac002</ArticleId><ArticleId IdType="pmc">PMC9914492</ArticleId><ArticleId IdType="pubmed">36846562</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf S., Zechmeister-Koss I., Erd&#xf6;s J. Possible long COVID healthcare pathways: a scoping review. BMC Health Serv Res. 2022;23(221):1076. doi: 10.1186/s12913-022-08384-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12913-022-08384-6</ArticleId><ArticleId IdType="pmc">PMC9396575</ArticleId><ArticleId IdType="pubmed">35999605</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMartino J.K., Swallow E., Goldschmidt D., Yang K., Viola M., Radtke T., et al. Direct health care costs associated with COVID-19 in the United States. J Manag Care Spec Pharm. 2022;28(9):936&#x2013;947. doi: 10.18553/jmcp.2022.22050. PMID: 35722829.</Citation><ArticleIdList><ArticleId IdType="doi">10.18553/jmcp.2022.22050</ArticleId><ArticleId IdType="pubmed">35722829</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger Z., Altiery de Jesus V., Assoumou S.A., Greenhalgh T. Long COVID and Health Inequities: The Role of Primary Care. Milbank Q. 2021;30(992):519&#x2013;541. doi: 10.1111/1468-0009.12505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1468-0009.12505</ArticleId><ArticleId IdType="pmc">PMC8241274</ArticleId><ArticleId IdType="pubmed">33783907</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroon S., Nirantharakumar K., Hughes S.E., Subramanian A., Aiyegbusi O.L., Davies E.H., et al. Therapies for Long COVID in non-hospitalised individuals: from symptoms, patient-reported outcomes and immunology to targeted therapies (The TLC Study) BMJ Open. 2022;12(4):e060413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9044550</ArticleId><ArticleId IdType="pubmed">35473737</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>